Enanta Receives EU Approval for Maviret for Acute HCV Infection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Enanta announced that the European Commission has approved Maviret, an oral pangenotypic direct-acting antiviral therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older. Maviret is now the only treatment approved in the European Union for both acute and chronic HCV infection.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENTA
Wall Street analysts forecast ENTA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.510
Low
17.00
Averages
18.50
High
20.00
Current: 14.510
Low
17.00
Averages
18.50
High
20.00
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Federal Court Rules in Favor of Pfizer in Patent Dispute with Enanta
- Patent Dispute Victory: The U.S. Court of Appeals for the Federal Circuit ruled in favor of Pfizer (PFE) in a patent dispute with Enanta Pharmaceuticals (ENTA), affirming the lower court's decision and demonstrating Pfizer's strong legal backing for its COVID-19 therapy Paxlovid.
- Patent Validity Confirmation: The court supported Pfizer's argument that Enanta's claimed U.S. Patent No. 11,358,953, obtained in 2022, was invalid, a ruling that not only protects Pfizer's market position but may also influence the development and commercialization of similar drugs in the future.
- Litigation Background: Enanta filed a lawsuit in 2022 in a Massachusetts federal court seeking damages from Pfizer for alleged patent infringement during the development of the COVID-19 pill, but the court's ruling dismissed Enanta's claims, further weakening its competitive stance in the industry.
- Market Impact Analysis: Pfizer's victory in this case will bolster investor confidence in its COVID-19 treatment market, potentially attracting more investment in its future product developments, while also setting a legal precedent for patent protection among other pharmaceutical companies.
See More
AbbVie and Enanta Gain EU Approval for Maviret Label Expansion
- Label Expansion Approval: AbbVie and Enanta's jointly developed hepatitis C therapy, Maviret, has received EU approval to be indicated for patients aged 3 and older with acute HCV infection, significantly broadening its market applicability.
- Significant Market Demand: Over 12 million individuals in Europe are infected with the hepatitis C virus, which can lead to severe complications such as cirrhosis and end-stage liver disease if untreated, highlighting the drug's potential and importance in addressing this public health issue.
- Clinical Trial Support: The approval is backed by results from late-stage trials demonstrating the efficacy of an eight-week regimen of Maviret, making it the only antiviral therapy available in the EU for both acute and chronic HCV infections, thereby enhancing its competitive edge.
- Strategic Implications: The label expansion of Maviret not only addresses the treatment needs of acute HCV patients but also lays the groundwork for AbbVie and Enanta's further expansion in the global market, strengthening their leadership position in the liver disease treatment sector.
See More
MAVIRET® Receives EU Approval for Acute HCV Treatment
- EU Approval: MAVIRET® (glecaprevir/pibrentasvir) is now the only treatment approved in the EU for both acute and chronic hepatitis C virus (HCV) infections, representing a significant advancement for over 12 million HCV patients by enabling immediate treatment at diagnosis, thereby reducing transmission and long-term liver complications.
- Clinical Trial Success: In a Phase 3 clinical trial involving 286 treatment-naïve patients with acute HCV infection, MAVIRET achieved a treatment success rate of 96.2%, demonstrating its high efficacy in acute HCV patients, with most adverse events reported as mild or moderate, ensuring patient safety.
- Public Health Impact: This approval accelerates treatment for HCV patients, particularly those who may be asymptomatic in the acute phase, thus supporting public health efforts to reduce HCV transmission, addressing unmet medical needs, and advancing HCV elimination initiatives.
- Strategic Collaboration: Enanta Pharmaceuticals' collaboration with AbbVie has facilitated the development and commercialization of MAVIRET, and they will continue to work with global regulatory authorities to ensure access to this critical treatment for patients with acute HCV infection.
See More
Enanta Pharmaceuticals Advances Zelicapavir Clinical Trials for RSV
- Clinical Trial Advancement: Enanta Pharmaceuticals announced the initiation of a registrational Phase 2b/3 clinical trial for Zelicapavir in high-risk adults with RSV, set to begin in Q4 2026, with topline data expected in 2027, marking a significant step forward in RSV treatment development.
- Pediatric Trial Plans: The company also plans to launch a Phase 2b clinical trial for pediatric patients with RSV in Q3 2026, with topline data anticipated in 2027, potentially providing a treatment option for children and expanding Zelicapavir's market application.
- Significant Market Opportunity: Enanta estimates that an oral RSV antiviral for children and all high-risk adults represents a global market opportunity exceeding $2 billion, with a potential addressable population of over 3 million patients in the U.S., highlighting Zelicapavir's commercial potential.
- Safety and Efficacy: Previous trials demonstrated Zelicapavir's significant efficacy in high-risk adults, reducing the time to complete resolution of symptoms by 6.7 days and achieving a hospitalization rate of 0%, establishing a strong foundation for its future market introduction.
See More
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
See More
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
See More
Federal Court Rules in Favor of Pfizer in Patent Dispute with Enanta
- Patent Dispute Victory: The U.S. Court of Appeals for the Federal Circuit ruled in favor of Pfizer (PFE) in a patent dispute with Enanta Pharmaceuticals (ENTA), affirming the lower court's decision and demonstrating Pfizer's strong legal backing for its COVID-19 therapy Paxlovid.
- Patent Validity Confirmation: The court supported Pfizer's argument that Enanta's claimed U.S. Patent No. 11,358,953, obtained in 2022, was invalid, a ruling that not only protects Pfizer's market position but may also influence the development and commercialization of similar drugs in the future.
- Litigation Background: Enanta filed a lawsuit in 2022 in a Massachusetts federal court seeking damages from Pfizer for alleged patent infringement during the development of the COVID-19 pill, but the court's ruling dismissed Enanta's claims, further weakening its competitive stance in the industry.
- Market Impact Analysis: Pfizer's victory in this case will bolster investor confidence in its COVID-19 treatment market, potentially attracting more investment in its future product developments, while also setting a legal precedent for patent protection among other pharmaceutical companies.
See More
AbbVie and Enanta Gain EU Approval for Maviret Label Expansion
- Label Expansion Approval: AbbVie and Enanta's jointly developed hepatitis C therapy, Maviret, has received EU approval to be indicated for patients aged 3 and older with acute HCV infection, significantly broadening its market applicability.
- Significant Market Demand: Over 12 million individuals in Europe are infected with the hepatitis C virus, which can lead to severe complications such as cirrhosis and end-stage liver disease if untreated, highlighting the drug's potential and importance in addressing this public health issue.
- Clinical Trial Support: The approval is backed by results from late-stage trials demonstrating the efficacy of an eight-week regimen of Maviret, making it the only antiviral therapy available in the EU for both acute and chronic HCV infections, thereby enhancing its competitive edge.
- Strategic Implications: The label expansion of Maviret not only addresses the treatment needs of acute HCV patients but also lays the groundwork for AbbVie and Enanta's further expansion in the global market, strengthening their leadership position in the liver disease treatment sector.
See More
MAVIRET® Receives EU Approval for Acute HCV Treatment
- EU Approval: MAVIRET® (glecaprevir/pibrentasvir) is now the only treatment approved in the EU for both acute and chronic hepatitis C virus (HCV) infections, representing a significant advancement for over 12 million HCV patients by enabling immediate treatment at diagnosis, thereby reducing transmission and long-term liver complications.
- Clinical Trial Success: In a Phase 3 clinical trial involving 286 treatment-naïve patients with acute HCV infection, MAVIRET achieved a treatment success rate of 96.2%, demonstrating its high efficacy in acute HCV patients, with most adverse events reported as mild or moderate, ensuring patient safety.
- Public Health Impact: This approval accelerates treatment for HCV patients, particularly those who may be asymptomatic in the acute phase, thus supporting public health efforts to reduce HCV transmission, addressing unmet medical needs, and advancing HCV elimination initiatives.
- Strategic Collaboration: Enanta Pharmaceuticals' collaboration with AbbVie has facilitated the development and commercialization of MAVIRET, and they will continue to work with global regulatory authorities to ensure access to this critical treatment for patients with acute HCV infection.
See More
Enanta Pharmaceuticals Advances Zelicapavir Clinical Trials for RSV
- Clinical Trial Advancement: Enanta Pharmaceuticals announced the initiation of a registrational Phase 2b/3 clinical trial for Zelicapavir in high-risk adults with RSV, set to begin in Q4 2026, with topline data expected in 2027, marking a significant step forward in RSV treatment development.
- Pediatric Trial Plans: The company also plans to launch a Phase 2b clinical trial for pediatric patients with RSV in Q3 2026, with topline data anticipated in 2027, potentially providing a treatment option for children and expanding Zelicapavir's market application.
- Significant Market Opportunity: Enanta estimates that an oral RSV antiviral for children and all high-risk adults represents a global market opportunity exceeding $2 billion, with a potential addressable population of over 3 million patients in the U.S., highlighting Zelicapavir's commercial potential.
- Safety and Efficacy: Previous trials demonstrated Zelicapavir's significant efficacy in high-risk adults, reducing the time to complete resolution of symptoms by 6.7 days and achieving a hospitalization rate of 0%, establishing a strong foundation for its future market introduction.
See More
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
See More
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
See More
